Breast Cancer Market1
-
Upload
anilpharma102 -
Category
Documents
-
view
216 -
download
0
Transcript of Breast Cancer Market1
-
8/8/2019 Breast Cancer Market1
1/9
The Cancer Market
Outlook to 2014
Competitive landscape, market size,
pipeline analysis and growth
opportunities
1995/2885/$3835
December 2009
Report Price
Publication date
H
EA
L
T
H
C
A
R
E
F o r a c l e a r e r m a r k e t p e r s p e c t i v e
-
8/8/2019 Breast Cancer Market1
2/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Business Insights portfolio of healthcare reports is designed to help you make
well informed and timely business decisions. We understand the problems
facing today's pharmaceutical and healthcare executives when trying to drive
your business forward, and appreciate the importance of accurate, up-to-date,incisive product, market and company analysis. We help you to crystallize your
business decisions.
Business Insights reports are authored by independent experts and contain findings from dedicated primary
research. Our authors' leading positions secure them access to interview key executives and to establish which
issues will be of greatest strategic significance for the industry.
Our healthcare portfolio of reports can be used across a wide range of business functions to assess market
conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis,
market outlook, new business opportunities and strategic insight.
Pages 194
Figures 15
Tables 76
This report provides wide
coverage across the major
cancer markets, and provides
an analysis of marketed and
pipeline drugs. It also
analyzes the growth trends
and future market leaders,
forecasting revenues andepidemiology through the
period 2008-14...
In the current decade, oncology has been one of the most important growth
segments among the pharmaceutical markets with a major focus on targeted
agents. Most innovation in oncology over the past 10 years has been driven by
scientific advances, particularly in genomics, transcriptomics and proteomics. In
the current environment, the successful oncology players of the future will be
those that can anticipate protocol evolution and design the most relevant clinical
trials. In recent years, biotech companies have fuelled innovation in oncology
more than ever before. Partnering with biotech companies is a key (but
expensive) source of innovation for many pharma companies as approximately
75% of phase II, III and pre-registration innovative drugs are of biotech origin.
At $47.7bn, cancer is one of the largest and fastest growing markets in the
pharmaceutical industry. However, pricing risk remains the key investment
concern in oncology. The key concern, however, is not price erosion driven by
competitive forces, but price cuts imposed by payors irrespective of the fact that
such unilateral price cuts by payors have never occurred in any of the major
developed markets and would surely jeopardize the premise on which the entire
biopharmaceutical industry has been built.
This report provides coverage of over 95% of the total market for cancer products and enables the reader to
understand the issues behind the market-leading products of today and forecasts the market-leading products of
tomorrow. The report allows the reader to understand which pharmaceutical companies will be the dominant forces in
the cancer arena, and which products will be the strongest performers over the period 2009-14.
About Us
Report Overview
-
8/8/2019 Breast Cancer Market1
3/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Key Findings
Use this report to...
In 2008, antineoplastic mAbs delivered huge sales
of $13.6bn with a market share of 28.6% of total
sales. The key antineoplastic mAbs which contributed to the
higher market share of this class in 2008 were MabThera(11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%).
Forecast sales of the total antineoplastics market are
estimated at $65.2bn in 2014.
Roche is the global market leader in cancer,
holding the highest market share of 29.2%
($14.0bn sales) in 2008 based on sales from (MabThera,
Avastin, Herceptin, Tarceva and Xeloda). Roches strength
in the cancer market has been bolstered by its acquisition of
Genentech and purchase of majority stakes in Chugai, whichhas provided additional breadth to its portfolio.
Eli Lillys acquisition of ImClone will increase the
formers flow of high-quality, innovative new
therapies. The transaction will immediately enable Eli Lilly to
offer physicians and their patients a complementary portfolio of
leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.
Pfizers axitinib, Dendreons Provenge and GSK/Genmabs Arzerra are expected to be the top sellers
among late stage pipeline oncolytic agents.
Figure 4.7: Key drugs in late-stage
development or that have been recently
launched
More than $47.7bn worth of cancer drugs were soldglobally in 2008 with US making up for 39.1% of these
sales. The value of novel targeted therapies, their
combinations with chemotherapy, and the potential of
adjuvant therapy have demonstrated to improve survival
rates, notably in breast, lung and colon cancers
Develop insight into patient potential with
the reports coverage of major indications in the
cancer segment, the seven largest geographic
pharmaceutical markets and 10 largest
companies active in the cancer segment today
Quickly understand how recent events are
affecting the performance of major products,
and how their marketers are confronting
competitive changes in cancer marketplace
Gain up-to-date competitive intelligence
across the cancer indications and understand
the major issues affecting key
pharmaceutical/biotech players
Understand which indications have the
greatest potential to provide franchise
growth, and how pharmaceutical companies
are attempting to exploit these opportunities
Compare the franchises of toppharmaceutical marketers across major
indications, and understand how market share
of leading companies will change over the next
6 years
Use head-to head comparisons of the leading
cancer pipeline compounds to understand
which companies will have a presence among
key indications over the next 6 years
-
8/8/2019 Breast Cancer Market1
4/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Key issues...
Discover...
FDA approves Cervarix for cervical cancer: In October 2009, FDA approved GSKs Cervarix for the
prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged
1025 years. Cervarixs inclusion in childrens vaccine program is a major step towards securing reimbursement.
Cervarix, expected to launch by the end of 2009, faces direct competition from Mercks Gardasil and will help toreduce the incidence of cervical cancer in future.
Mercks Gardasil adds US indication of genital warts for boys and men: On 16th October 2009,
Gardasils US label was extended to include its use in both men and boys aged 926 years of age. The
pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types
6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free
Gardasil to 1926 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.
Roches Avastin filed for first-line breast cancer in Japan: In October 2009, Roches Japanese
subsidiary, Chugai has filed a Japanese approval for Avastin in the first-line treatment of advanced orrecurrent breast cancer. The filing in first-line breast cancer was supported by an international Phase III trial (first-
line setting), which showed a significant improvement in PFS. This in turn was supported by Japanese Phase II
safety and efficacy data. Approval of the product will expand Avastins purview beyond colon cancer in the
country, becoming growth driving event.
Eisai to file first in-house breast cancer drug in major markets: Eisai is planning to file its in-house
developed chemotherapy drug eribulin for pre-treated breast cancer (advanced or metastatic) in all the
major markets (US, 5EU & Japan) by March 2010. Preliminary results from the key Phase III trial demonstrated a
significant improvement in overall survival, the primary endpoint.
What will be the major growth indications in
the cancer segment over the period 200814?
Which companies were the winners and losers
in the cancer segment in 2008?
How have recent major launches from
companies such as Roche, Sanofi-Aventis,
AstraZeneca, Novartis and Eli Lilly performed?
Which companies will become the key players
in the cancer segment over the period
200814?
Which products will be impacted by generic
competitors over the period 200814?
Which pipeline products will be the growth
drivers of the future?
Which indications are forecast to have the
highest levels of market potential over the
period 200814?
What will the competitive landscape in lung,
breast, colorectal, ovarian, prostate, lymphoma
and pancreatic cancer in 2014?
-
8/8/2019 Breast Cancer Market1
5/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Table of Contents
EXECUTIVE SUMMARY
Epidemiology of Cancer
Global Market Analysis
Pipeline Analysis
Competitive Landscape
CHAPTER 1 SCOPE AND
METHODOLOGY
Scope
Methodology
CHAPTER 2 OVERVIEW AND
EPIDEMIOLOGY OF CANCER
INDICATIONS Summary
Introduction
Overview
Cancer risk factors
Lung cancer
- Overview
- Diagnosis, treatment and
management
- Epidemiology- NSCLC
- SCLC
- Forecast epidemiology- NSCLC
- SCLC
Colorectal cancer
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Breast cancer
- Overview- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Ovarian cancer
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Uterine and cervical cancer
- Overview
- Diagnosis, treatment and
management- Epidemiology
- Forecast epidemiology
Leukemia
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Prostate cancer
- Overview
- Diagnosis, treatment andmanagement
- Epidemiology
- Forecast epidemiology
Pancreatic cancer
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Lymphomas
- Overview- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
Head and neck cancer
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
CHAPTER 3 GLOBAL MARKET
ANALYSIS
Summary
Introduction
Market analysis by country
Market analysis by drug class
Leading brand dynamics
- MabThera (rituximab)
Roche/Genentech
- Avastin (bevacizumab)
Roche/Genentech
- Herceptin (trastuzumab)
Roche/Genentech/Chugai
- Glivec/Gleevec (imatinib)
Novartis- Taxotere (docetaxel) Sanofi-
Aventis
Leading brands by type of cancer
Key recent events in the cancer
market
- FDA approves Cervarix for
cervical cancer
- Merck's Gardasil adds US
indication of genital warts for
boys and men
- Roche's Avastin is filed for first-line breast cancer in Japan
- Eisai to file first in-house breast
cancer drug in major markets
- Novartis's Tasigna bolsters its
CML franchise
Antineoplastics
- Competitive dynamics of
antineoplastics
- Leading brands of
antineoplastics
- Antineoplastic mAb marketanalysis- Market dynamics
- Key brands analysis
- Antineoplastic protein kinase
inhibitors- Market dynamics
- Key brands analysis
- Vinca alkaloid market analysis- Market dynamics
- Key brands analysis
- Anti-metabolites- Market dynamics
- Key brands analysis
- Platinum compounds- Market dynamics
- Key brands analysis
- Antineoplastic sales forecast
Cytostatic hormonal therapies
- Competitive dynamics of
cytostatic hormonal therapies
- Leading brands of cytostatic
hormonal therapies
- Cytostatic gonad hormone
analog market analysis
-
8/8/2019 Breast Cancer Market1
6/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Table of Contents
- Market dynamics
- Key brands analysis
- Aromatase inhibitors- Market dynamics
- Key brands analysis
- Anti-androgens- Market dynamics
- Key brand analysis
- Cytostatic hormonal therapy
sales forecast
- Global cancer market sales
forecast
CHAPTER 4 PIPELINE ANALYSIS
Summary
Introduction
Key trends in R&D
- Targeted therapies are changing
the treatment regimen of cancer
- Biomarkers are personalizing
oncology treatment
- Cancer vaccines enhance the
body's immune response
- Pricing is becoming a major
issue for cancer patients
- Combination treatments are
becoming the treatment ofchoice
Leading drugs in development
- Phase III and pending approval
compounds- Enzastaurin Eli Lilly
- BiovaxID Biovest International
and Accentia Biopharmaceuticals
- Recentin (cediranib) AstraZeneca
- Zactima (vandetanib)
AstraZeneca
- Axitinib (AG-13736) Pfizer
- Provenge (sipuleucel-T) Dendreon
- Recently approved/marketed
drugs- Arzerra (ofatumumab)
GSK/Genmab
- Afinitor (everolimus) Novartis
- Iressa (gefitinib) AstraZeneca
- Tykerb/Tyverb (lapatinib) GSK
- Votrient (pazopanib) GSK
Pipeline forecast of key compounds
- Factors affecting forecasts
CHAPTER 5 COMPETITIVE
LANDSCAPE
Summary
Introduction
- Sales performance of leading
players
Roche
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
SanofiAventis- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
AstraZeneca
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
Novartis
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
Eli Lilly
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
Pfizer
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
Takeda
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
Bristol-Myers Squibb
- Sales focus by drug class
- Regional sales distribution
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis- Drivers of growth
- Resistors of growth
CHAPTER 6 APPENDIX
IMS Data
- Antineoplastic and
immunomodulating agents- L1: Antineoplastics
- L2: Cytostatic hormone therapy
- Forecast factors
- Glossary- Abbreviations used in this report
- Index
LIST OF FIGURES
Types of breast cancers
Types of leukemia
Chemotherapy options forHodgkin's disease
Head and neck cancers and their
risk factors
Worldwide cancer market share by
region, 2008
Current pharmacological treatment
options for cancer
Key drugs in late-stage
development or that have been
recently launched
-
8/8/2019 Breast Cancer Market1
7/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Table of Contents
Contribution of the top 10 players
to growth of the global cancer
market, 200708
Roche's cancer sales by drug class,2008
SanofiAventis's cancer sales by
drug class, 2008
AstraZeneca's cancer sales by drug
class, 2008
Novartis's cancer sales by drug
class, 2008
Pfizer's cancer sales by drug class,
2008
Takeda's cancer sales by drug class,
2008 BMS' cancer sales by drug class,
2008
LIST OF TABLES
Estimated prevalence of NSCLC
across seven major markets, 2008
Estimated prevalence of SCLC
across seven major markets, 2008
Forecast epidemiology of NSCLC
across seven major markets,
200814
Forecast epidemiology of SCLC
across seven major markets,
200814
Estimated prevalence of colorectal
cancer across seven major markets,
2008
Forecast epidemiology of colorectal
cancer across seven major markets,
200814
Estimated prevalence of breast
cancer across seven major markets,
2008
Forecast epidemiology of breast
cancer across seven major markets,
200814
Estimated prevalence of ovarian
cancer across seven major markets,
2008
Forecast epidemiology of ovarian
cancer across seven major markets,
200814
Estimated prevalence of uterine and
cervical cancer across seven major
markets, 2008
Forecast epidemiology of uterineand cervical cancer across seven
major markets, 200814
Estimated prevalence of leukemia
across seven major markets, 2008
Forecast epidemiology of leukemia
across seven major markets,
200814
Estimated prevalence of prostate
cancer across seven major markets,
2008
Forecast epidemiology of prostatecancer across seven major markets,
200814
Estimated prevalence of pancreatic
cancer across seven major markets,
2008
Forecast epidemiology of
pancreatic cancer across seven
major markets, 200814
Estimated prevalence of lymphomas
across seven major markets, 2008
Forecast epidemiology oflymphomas across seven major
markets, 200814
Estimated prevalence of head and
neck cancer across seven major
markets, 2008
Forecast epidemiology of head and
neck cancer across seven major
markets, 200814
Global cancer market by geography,
2008
Breakdown of the global cancermarket by drug class, 2008
Leading brands in the global cancer
market, 2008
Leading brands in breast cancer,
2008
Leading brands in colon cancer,
2008
Leading brands in prostate cancer,
2008
Leading brands in lung cancer, 2008
Breakdown of the global
antineoplastic market by drug class,
2008
Leading brands in globalantineoplastics market, 2008
Chronology of new indication
approvals for Eloxatine
Antineoplastic sales forecast,
200814
Breakdown of the global cytostatic
hormonal therapies by drug class,
2008
Leading brands in global cytostatic
hormonal therapies market, 2008
Cytostatic hormonal therapy salesforecast, 200814
Global cancer market sales forecast,
200814
An overview of enzastaurin
An overview of BiovaxID
An overview of Recentin
The Horizon Study Program
An overview of Zactima
Overview of Zactimas Phase III
development plan
An overview of axitinib
An overview of Provenge
An overview of Arzerra
An overview of Afinitor
An overview of Iressa
An overview of Tykerb/Tyverb
An overview of Votrient
Key pipeline and recently approved
products sales forecast, 200814
Leading players in the global cancer
market, 200814 Regional sales distribution of Roche,
2008
Roche's cancer product portfolio,
2008
Roche's cancer R&D product
pipeline, October 2009
Regional sales distribution of Sanofi-
Aventis, 2008
SanofiAventis's cancer product
portfolio, 2008
-
8/8/2019 Breast Cancer Market1
8/9
The Cancer Market Outlook to 2014
Competitive landscape, market size, pipeline analysis and growth opportunities
Table of Contents
Sanofi-Aventis's cancer R&D
product pipeline, October 2009
Regional sales distribution of
AstraZeneca, 2008 AstraZeneca's cancer product
portfolio, 2008
AstraZeneca's cancer R&D product
pipeline, October 2009
Regional sales distribution of
Novartis, 2008
Novartis' cancer product portfolio,
2008
Novartis's cancer R&D product
pipeline, October 2009
Regional sales distribution of Eli
Lilly, 2008
Eli Lilly's cancer product portfolio,
2008
Eli Lilly's cancer R&D product
pipeline, October 2009
Regional sales distribution of Pfizer,
2008
Pfizer's cancer product portfolio,
2008
Pfizer's cancer R&D product
pipeline, October 2009
Regional sales distribution of
Takeda, 2008
Takeda's cancer product portfolio,
2008
Takeda's cancer R&D product
pipeline, October 2009
Regional sales distribution of BMS,
2008
BMS' cancer product portfolio, 2008
BMS' cancer R&D product pipeline,October 2009
-
8/8/2019 Breast Cancer Market1
9/9
+44 (0) 207 900 6688FAX BACK TO:
Company details
3
Company name: ________________________________________________________
EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:
_____________________________________________________________________________________________
Purchase Order Number (if required)_____________________________________
Recipient details (If different from Payor)
Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS)
First Name: Last Name:
Email
Job Title
Department
Address
City State/Province
Country Post Code/ZIP
Tel Fax
Payment method
Please indicate your preferred currency: GB EUR US$Total order value is ____________________________
I will forward a check payable to Business Insights Limited.
Please invoice my company (please complete invoice address below)
I would like to pay by bank transfer (email address required)
Debit my credit/charge card: Amex Visa Mastercard
Card No________________________________________________________________________
Expiry Date _________ / _________ Signature ______________________________
4
Sign here to confirm your order:
ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED
Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS)
First Name: Last Name:
Email
Job Title
Department
Address
City State/Province
Country Post Code/ZIP
Tel
Fax
Payor details 5
or scan and e-mail to
Interactive VersionA new, innovative way to view our publications
Customize, search, translate, contrast,
manipulate and extract report content.
- Add 50/75/$95per report
Hard CopyPlease fill out recipient derails below if you wish
to order a printed version of your report(s).
- Add 50/75/$95per report- Please allow 28 days for delivery
I would like to order the following report(s)...1
1.____________________________________________________
2.____________________________________________________
3.____________________________________________________
Ordering Multiple reports:
Email/Fax/Postal promotion
Brochure
Table of Contents
Colleague Recommendation
Trade Press
My Account Manager
Conference materials
Website/web search
Communications FeedbackPlease let us know if any of the following factors influenced your purchase...
(Please use BLOCK CAPITALS)
2
1 report ___________________________
2 reports - save 15% ___________________________3 reports - save 20% ___________________________
Multiple report discounts
1. Price is for a Single User licence
2. Discount applied to sum of total list price. Cannot be used in conjunction with other offers.
3. Contact [email protected] for more information on regional/global licence s
Enter total price below
About Business Insights
Business Insights appreciate the importance of accurate, up-to-date incisive
market and company analysis and our aim therefore is to provide a single,
off-the-shelf, objective source of data, analysis and market insight.
www.globalbusinessinsights.com